TMV vaccine

The TMV vaccine is an experimental, personalized cancer immunotherapy developed by researchers at Emory University for the treatment of triple-negative breast cancer (TNBC). The vaccine platform utilizes the Tobacco Mosaic Virus (TMV), a plant virus, as a non-infectious, highly organized nanoparticle scaffold. To create the vaccine, tumor membrane vesicles (TMVs) are harvested from a patient's own tumor tissue and chemically conjugated to the surface of the TMV particles. This approach allows for the presentation of a diverse array of patient-specific tumor-associated antigens to the immune system. The TMV scaffold itself acts as an adjuvant, stimulating innate immune pathways to enhance the T-cell mediated anti-tumor response. It is currently being evaluated in Phase I clinical trials as a monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab or ipilimumab to prevent recurrence in patients with early-stage or metastatic TNBC.

Other names

Personalized tumor membrane vesicle vaccineTobacco mosaic virus-based vaccineTMV-based vaccineTMV-TNBC vaccine